Inclusion Criteria:  Patients who are willing to participate in this study Adults aged ≥ 18 years old presented at the clinic with a confirmed diagnosis of T2DM who are on sulfonylurea for the last 6 months at least and diagnosed with NAFLD.  Exclusion Criteria:  • Patients who refused to participate in this trial  Patients diagnosed with Type 1 diabetes Previous history of alcohol intake history of recurrent attacks of ketoacidosis in a diabetic patient Type 2 diabetic patient with kidney dysfunction (estimated eGFR below 60ml/min/1.73m2 or CrCl below 60ml/min) or on dialysis Previous history of taking medication that may alter either drug efficacy (eg, corticosteroids, oral contraceptives, and thiazide diuretics) Evidence of another liver disease (viral hepatitis, drug-induced liver disease, autoimmune hepatitis) Lactating/pregnant female or children ≤ 18  Any contraindication for Empagliflozin including:  History of recurrent attacks of UTI or Genital infection in females History of recurrent foot injuries or infections Type 2 diabetic patient with CV disease especially NYHA classes III/ IV Immunocompromised patients or with a history of inflammatory, immunological, or malignant diseases.  Any contraindication for PTX including:  Hypersensitivity to PTX Patients with peptic ulcer disease or tendency for bleeding  Any contraindication for UDCA including:  Hypersensitivity to UDCA Patients with biliary disease or hepatobiliary disease (ascites, jaundice) Patients with hepatic encephalopathy or gallstone pancreatitis